Everolimus - CAS 159351-69-6
Catalog number: 159351-69-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cytokine-mediated lymphocyte proliferation. Everolimus can be used as an immunosuppressant in the treatment of renal cell cancer and other cancers.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
inhibitor of mTOR, immunosuppressant
Off-White to Pale Yellow Solid
Afinitor; Certican; Zortress; RAD001; SDZ-RAD; 40-O-(2-Hydroxyethyl)rapamycin; 42-O-(2-Hydroxy)ethyl Rapamycin
Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.
Shelf Life:
2 years
Melting Point:
107-113 °C
Canonical SMILES:
1. Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry
Matthew A. Gregory, Andrew L. Kaja, Barrie Wilkinson*. Chem. Sci., 2013, 4, 1046–1052
Rapamycin is a polyketide natural product produced by Streptomyces rapamycinicus NRRL5491. The intracellular receptor of 1 is the 12 kDa FK506 binding protein,(FKBP12). The 1–FKBP12 complex is a highly selective and potent inhibitor of mammalian/mechanistic target of rapamy- cin complex 1 (mTORC1) at sub-nanomolar concentrations. Rapamycin is used clinically as an immunosuppressant after organ transplantation (Rapamune) and for the prevention of restenosis after stent insertion for the treatment of coronary heart disease (e.g. Cypher).Semi-synthetic derivatives of Rapamycin including temsirolimus (Torisel) and everolimus (Afinitor) are both approved for the treatment of renal cell carcinoma and other proliferative diseases. Further rapamycin analogues (rapalogs) have shown potential for the treatment of cardiovascular, autoimmune and neurodegenerative diseases.
2. Biosynthetic medicinal chemistry of natural product drugs
Frank E. Koehn*. Med. Chem. Commun., 2012, 3, 854–865
Rapamycin (sirolimus) is a 31-membered macrocyclic polyketide produced by Streptomyces hygroscopicus. It was discovered on the basis of its antifungal activity and then soon was shown to have potent anti-proliferative/immunosuppressive effects. Rapamycin and its analogues exert their antiproliferative effect by inhibition of mTOR (mammalian target of rapamycin) via FKBP-12-mediated formation of a ternary complex. The powerful anti-proliferative activity of rapamycin have been harnessed clinically to treat organ transplant rejection, and further development has furnished three semisynthetic analogues- temsirolimus (2) and everolimus (34) which are both approved for treatment of advanced renal cancer, and ridaforolimus (35) which is in late stage clinical trial for the treatment of metastatic soft-tissue and bone cancer. (Fig. 6) In contrast to FK506, rapamycin has been the subject of considerable biosynthetic medicinal investigation, and serves as a good example of what is possible with modular polyketide systems.
3. The metamorphosis of vascular stents: passive structures to smart devices
Purandhi Roopmani, Swaminathan Sethuraman, Santhosh Satheesh and Uma Maheswari Krishnan*. RSC Adv.,2016, 6,2835–2853
The initial success with sirolimus had triggered a search of sirolimus analogues that possess similar anti-proliferative effect but lesser adverse effects. Among these analogues, everolimus (a new macrocylic triene derivative), biolimus A9, immunosuppressive agents such as cyclosporine, mycophenolic acid and tacrolimus, which induce G1 arrest leading to reduced proliferation and immune response, have been incorporated in stents. Everolimus is a macrolide antibiotic that possesses the ability to suppress the immune response and cell proliferation leading to prevention of restenosis similar to sirolimus. It possesses greater polarity than sirolimus and hence has better bioavailability and is rapidly absorbed on the arterial wall and attains peak concentration within few hours thereby offering better efficacy. Experimental data have shown that orally administered everolimus inhibits in-stent neointimal formation and significantly promotes neointimal healing. Evorolimus has been found to act at a later stage than the calcineurin inhibitor cyclosporin and tacrolimus.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products

CAS 162635-04-3 Temsirolimus

(CAS: 162635-04-3)

Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM.

CAS 1246535-95-4 Desmethyl-VS-5584

(CAS: 1246535-95-4)

Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.

CAS 1013098-90-2 PI3Kα/mTOR-IN-1

(CAS: 1013098-90-2)

PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).

CAS 1197160-78-3 Gedatolisib (PF-05212384, PKI-587)

Gedatolisib (PF-05212384, PKI-587)
(CAS: 1197160-78-3)

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.

CAS 1009298-09-2 AZD-8055

(CAS: 1009298-09-2)

AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...

CAS 1092351-67-1 PP242

(CAS: 1092351-67-1)

PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...

CAS 1092788-83-4 PP121

(CAS: 1092788-83-4)

PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kin...

CAS 936890-98-1 OSI-027

(CAS: 936890-98-1)

mTOR kinase inhibitor OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinas...

CAS 53123-88-9 Rapamycin

(CAS: 53123-88-9)

Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...

CAS 1429639-50-8 CZ415

(CAS: 1429639-50-8)

CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...

CAS 1028385-32-1 BEZ235 Tosylate

BEZ235 Tosylate
(CAS: 1028385-32-1)

BEZ235 tosylate is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assay...

(CAS: 1927857-61-1)

PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...

(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

CAS 1032754-93-0 Apitolisib

(CAS: 1032754-93-0)

Apitolisib, also known as GDC-0980 and RG7422;  or GNE390, is a dual PI3 kinase/mTOR inhibitor,   is also an orally available agent targeting phosphatidylinosit...

CAS 154447-38-8 LY 303511

LY 303511
(CAS: 154447-38-8)

PI3K inhibitory activity. Inhibits voltage-gated Kv channel activity (IC50 = 64.6 μM). Various pharmacological effects including inhibition of LPS-stimulated FP...

CAS 572924-54-0 Ridaforolimus

(CAS: 572924-54-0)

Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...

CAS 1676893-24-5 NSC781406

(CAS: 1676893-24-5)

NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.

(CAS: 57818-44-7)

ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with p...

CAS 1033735-94-2 GNE-493

(CAS: 1033735-94-2)

GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively...

CAS 1224844-38-5 MLN0128

(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

Chemical Structure

CAS 159351-69-6 Everolimus

Quick Inquiry

Verification code

Featured Items